Use of a GABA-transaminase agonist for treatment of infantile autism.
This paper describes the use of a GABA-transaminase agonist for the treatment of infantile autism. An approximate one third reduction of GABA and ammonia levels for an autistic patient with noticeable improvement of verbal/language skills and a reduction of repetitious ritualistic self-stimulatory behavior (stimming) was observed. A reduction of the plasma GABA (by administrating a GABA-T agonist, Imipramine) probably results in more axon(s)-to-oligodendrocyte signaling in the corpus callosum and it is postulated that this could result in a reduction of the autistic features for the patient.
Cohen
Brett I
BI
ED Laboratories, S. Hackensack, New Jersey 07606, USA. EDS@Pipeline.com
D000612:4-Aminobutyrate Transaminase / Q000187:drug effects*; D001321:Autistic Disorder / Q000188:drug therapy*; D018755:GABA Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007099:Imipramine / Q000494:pharmacology / Q000627:therapeutic use*; D007223:Infant
D018755:GABA Agonists; D000612:4-Aminobutyrate Transaminase; D007099:Imipramine